Prevalence of Kaposi's sarcoma-associated herpesvirus and transfusion-transmissible infections in Tanzanian blood donors.
Adolescent
Adult
Blood Donors
Cross-Sectional Studies
Female
HIV Infections
/ epidemiology
HIV-1
Herpesviridae Infections
/ epidemiology
Herpesvirus 8, Human
/ immunology
Humans
Male
Middle Aged
Prevalence
Risk Factors
Sarcoma, Kaposi
/ epidemiology
Seroepidemiologic Studies
Syphilis
/ epidemiology
Tanzania
/ epidemiology
Transfusion Reaction
Blood donors
KSHV prevalence
Tanzania
Transfusion-transmissible infections
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
08
03
2020
revised:
02
04
2020
accepted:
04
04
2020
pubmed:
16
4
2020
medline:
29
7
2020
entrez:
16
4
2020
Statut:
ppublish
Résumé
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent for Kaposi's sarcoma (KS), one of the most common cancers in Tanzania. We have investigated KSHV prevalence and factors associated with KSHV infection in Tanzania. This is a cross-sectional study of voluntary blood-donors from Dar es Salaam, Tanzania. Plasma was screened for KSHV, HIV-1, HBV, HCV and Treponema pallidum (syphilis). Associations between KSHV sero-status and risk factors were analyzed. Odds ratios (OR) and 95% confidence intervals (CI) are reported to evaluate risk factors of KSHV infection. All tests were 2-tailed, and P-values <0.05 were considered statistically significant. The overall KSHV seroprevalence was 56.9%. Significantly increased risk of KSHV infection was detected in persons from the Lake and Central Zones (OR=6.4, 95% CI=1.6-25.3, P=0.008 and OR=5.7, 95% CI=1.0-32.5, P=0.048 respectively). A trend toward increased risk of KSHV infection with HIV-1 co-infection was not significant (OR=2.8, 95% CI=1.0-8.0, P=0.06). Seroreactivity to T. pallidum was surprisingly high (14.9%). The prevalence of KSHV infection and syphilis was high among Tanzanian blood-donors. The most common transfusion-transmissible infections did not associate with KSHV infection. Regions of focal KSHV infection need further investigation for underappreciated risk factors.
Identifiants
pubmed: 32294540
pii: S1201-9712(20)30234-4
doi: 10.1016/j.ijid.2020.04.018
pmc: PMC7917156
mid: NIHMS1669240
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
204-209Subventions
Organisme : FIC NIH HHS
ID : K43 TW011418
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190155
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Trop Med Int Health. 1998 Sep;3(9):757-63
pubmed: 9754673
N Engl J Med. 1995 May 4;332(18):1181-5
pubmed: 7700310
BMC Hematol. 2018 Dec 20;18:36
pubmed: 30598827
AIDS. 1997 Nov;11(13):1619-26
pubmed: 9365767
PLoS One. 2018 Oct 25;13(10):e0206487
pubmed: 30359434
J Med Virol. 2002 Oct;68(2):264-7
pubmed: 12210417
J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):547-54
pubmed: 25393941
Tumori. 1995 Sep-Oct;81(5):308-14
pubmed: 8804445
PLoS One. 2018 Dec 21;13(12):e0209586
pubmed: 30576388
J Med Virol. 2010 Sep;82(9):1569-75
pubmed: 20648611
BMC Infect Dis. 2015 Sep 23;15:386
pubmed: 26399765
Am J Med. 1981 Nov;71(5):779-83
pubmed: 7304649
J Pediatric Infect Dis Soc. 2013 Dec;2(4):320-6
pubmed: 24363930
Br J Cancer. 1998 Dec;78(11):1521-8
pubmed: 9836488
Pediatr Infect Dis J. 2018 Aug;37(8):e225-e228
pubmed: 29369149
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):300-8
pubmed: 24296855
Int J Cancer. 2003 Jan 10;103(2):233-40
pubmed: 12455038
Blood. 1995 Aug 15;86(4):1276-80
pubmed: 7632932
Int J Cancer. 2014 Dec 1;135(11):2644-52
pubmed: 24729433
J Med Virol. 2003 Nov;71(3):360-6
pubmed: 12966540
J Infect Dis. 2018 Jan 4;217(2):263-269
pubmed: 29099933
J Blood Transfus. 2016;2016:8546803
pubmed: 28070449
World J Gastroenterol. 2012 Sep 14;18(34):4677-83
pubmed: 23002336
Virol Sin. 2017 Oct;32(5):396-403
pubmed: 29116591
Int J Cancer. 2013 Mar 1;132(5):1182-90
pubmed: 22815207
J Infect Dis. 2003 Jun 1;187(11):1780-5
pubmed: 12751036
N Engl J Med. 1995 May 4;332(18):1186-91
pubmed: 7700311
East Afr Med J. 1999 Mar;76(3):167-71
pubmed: 10442119
J Infect Dis. 2009 May 15;199(10):1449-56
pubmed: 19351262
J Trop Med. 2018 Jan 30;2018:4239646
pubmed: 29666656
Cancer Med. 2016 May;5(5):914-28
pubmed: 26823008
Gastroenterol Clin North Am. 2011 Jun;40(2):355-72, viii
pubmed: 21601784
Lancet. 1993 Nov 27;342(8883):1348-51
pubmed: 7901641
Viruses. 2014 Nov 04;6(11):4178-94
pubmed: 25375883
Int J Cancer. 2010 Nov 15;127(10):2395-401
pubmed: 20143397
Clin Vaccine Immunol. 2008 Aug;15(8):1259-64
pubmed: 18508931
Int J Cancer. 2019 Nov 1;145(9):2468-2477
pubmed: 31265124
Int J Med Sci. 2005;2(1):50-57
pubmed: 15968340
J Infect Dis. 2009 Aug 1;200(3):430-8
pubmed: 19534596
Am J Epidemiol. 2008 Aug 1;168(3):311-20
pubmed: 18515794
Curr Opin HIV AIDS. 2009 Jan;4(1):22-6
pubmed: 19339936
EMBO J. 2008 Dec 17;27(24):3300-10
pubmed: 19020517
Int J Cancer. 2015 Mar 1;136(5):1241-2
pubmed: 25196932
Br J Cancer. 2003 Jan 13;88(1):1-3
pubmed: 12556950
Clin Microbiol Infect. 2014 May;20(5):475-81
pubmed: 23992104
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879
BMC Public Health. 2006 Jan 30;6:21
pubmed: 16445860
PLoS Negl Trop Dis. 2019 Oct 16;13(10):e0007776
pubmed: 31618208